久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
World
Home / World / Europe

BioNTech revenues boosted by COVID-19 vaccine programs

Xinhua | Updated: 2020-11-11 05:13
Share
Share - WeChat
Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. [Photo/Agencies]

BERLIN, Nov. 10 (Xinhua) -- German pharmaceutical company BioNTech SE announced on Tuesday that its revenues climbed to 136.9 million euros (161.7 million U.S. dollars) in the first nine months of the year, compared with 80.6 million euros in the same period last year.

The development of revenues was driven by new collaborations with U.S. company Pfizer and China's Fosun Pharma within the BNT162 vaccine program against COVID-19, according to the German company.

"We have initiated the first rolling regulatory submission processes for our COVID-19 vaccine program in the EU (European Union), the UK and Canada and we are continuing to work with our partners to scale-up production capacity to prepare for a potential global launch of our COVID-19 vaccine, if approved," said Ugur Sahin, chief executive officer (CEO) of BioNTech, in a statement.

In August, BioNTech and China's Fosun Group already started a Phase 1 study to evaluate safety and immunogenicity of the vaccine candidate in Chinese participants. BioNTech is expecting to start a Phase 2 clinical trial in China by the end of the year, once regulatory approval from China's National Medical Products Administration (NMPA) was granted.

On Monday, BioNTech and Pfizer announced that their vaccine candidate showed more than 90 percent efficacy in protecting against COVID-19 in volunteers with no proven previous SARS-CoV-2 infection.

Furthermore, no serious side effects had been observed based on first interim results from the ongoing Phase 3 clinical study conducted by an external, independent Data Monitoring Committee (DMC), according to a joint statement by the companies.

"Yesterday's announcement regarding the first interim analysis from our global Phase 3 trial for our COVID-19 vaccine candidate, BNT162, is a watershed moment for both our company and scientific innovation," stressed Sahin.

BioNTech and Pfizer are planning to submit their potential COVID-19 vaccine candidate for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) in the third week of November.

For the development of a COVID-19 vaccine, BioNTech received 375 million euros from a special vaccine development program by the German government. The progress made by BioNTech and Pfizer was "very encouraging," German Minister of Health Jens Spahn said during a press conference on Monday.

Spahn emphasized that the European Commission had the mandate to negotiate with pharmaceutical companies at the European level. In a statement issued on Tuesday, the Commission said it will authorize on Wednesday a contract for up to 300 million doses of the vaccine developed by BioNTech and Pfizer.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 泰国一级毛片aaa下面毛多 | 国产一级大片免费看 | 免费成年网| 国产亚洲精品一区999 | 一个人的视频日本免费 | 亚洲网站一区 | 黄色国产网站 | 国产高清一区二区三区 | 久久韩国| 91精品欧美综合在线观看 | 国产日韩欧美 | 国产一级一片免费播放刺激 | 国产精品91在线 | 国内欧美一区二区三区 | 国产三级成人 | 日本高清色视频www 日本高清在线精品一区二区三区 | 天堂8中文在线最新版在线 天堂8资源8在线 | 欧美性三级 | 一区二区三区免费在线观看 | 97免费视频免费视频 | 一级特级aaaa毛片免费观看 | 欧美日韩精品一区二区三区 | 国产午夜精品理论片免费观看 | 成人影院在线免费观看 | 亚洲欧美综合国产不卡 | 久久成年片色大黄全免费网站 | 国内精品91最新在线观看 | 一级床上爽高清播放 | 亚洲欧美日韩高清在线看 | 亚洲区一区 | 交视频在线观看国产网站 | 手机在线播放视频 | 欧美成人免费全部观看天天性色 | 国产欧美日韩综合精品一区二区 | 国产成人精品男人免费 | 欧美亚洲国产精品久久久久 | 精品九九视频 | 久久精品在线 | 国产美女又黄又爽又色视频免费 | 全免费毛片在线播放 | 波多野结衣在线观看免费区 |